K562 Cell Sensitization to 5-Fluorouracil- or Interferon-Alpha-Induced Apoptosis Via Cordycepin (3′-Deoxyadenosine): Fine Control of Cell Apoptosis Via Poly(A) Polymerase Upregulation
Free accessResearch articleFirst published online January, 2004
K562 Cell Sensitization to 5-Fluorouracil- or Interferon-Alpha-Induced Apoptosis Via Cordycepin (3′-Deoxyadenosine): Fine Control of Cell Apoptosis Via Poly(A) Polymerase Upregulation
K562 cells represent a classical model for the study of drug resistance. Induction of apoptosis is accompanied by concomitant distinct modulations of poly(A) polymerase (PAP) and other proteins involved in mRNA maturation. Recent data suggest the involvement of mRNA stability in the induction of specific apoptosis pathways. In this study we used a specific polyadenylation inhibitor, cordycepin (3-deoxyadenosine), to investigate the involvement of polyadenylation in K562 cell apoptosis and drug resistance. The combination of cordycepin with either 5-fluorouracil or interferon-alpha sensitized chemoresistant K562 cells to apoptosis. This sensitization was followed by distinct PAP modulations before and after the appearance of characteristic apoptosis pointers (DNA laddering, DAPI staining, mitochondrial transmembrane potential). PAP modulations appeared essential for K562 sensitization. mRNA polyadenylation therefore seemed to be involved not only in apoptosis but also in drug resistance. Polyadenylation inhibition by cordycepin under certain conditions sensitized chemoresistant K562 cells to apoptosis and thus polyadenylation could prove to be a fine target for overcoming drug resistance.
KaufmannS.H., EarnshawW.C.. Induction of apoptosis by cancer chemotherapy.Exp Cell Res2000; 256: 42–9.
2.
ThompsonC.B.. Apoptosis in the pathogenesis and treatment of disease.Science1995; 267: 1465–2.
3.
RobertsonJ.D., FadeelB., ZhivotovskyB., OrreniusS.. Centennial novel conference on apoptosis and human disease.Cell Death Differ2002; 9: 468–75.
4.
MullauerL., GruberP., SebingerD., BushJ., WolhfartS., ChottA.. Mutations in apoptosis genes: a pathogenic factor for human disease.Mut Res2001; 488: 211–31.
5.
SleeE.A., AdrianC., MartinS.J.. Serial killers: ordering caspase activation events in apoptosis.Cell Death Diff1999; 6: 1067–74.
6.
RobertsonD.J., EnokssonM., SuomelaM., ZhivotovskyB., OrreniusS.. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis.J Biol Chem2002; 277: 29803–9.
7.
SionovV.R., HauptY.. The cellular response to p53: the decision between life and death.Oncogene1999; 18: 6145–57.
8.
JurkenM., ManfredV.. Multiple pathway drug resistance.Int J Oncol1993; 2: 557–61.
9.
Segal-BendirjianE., Jacquemin-SablonA.. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process.Exp Cell Res1995; 218: 201–12.
10.
WuG.S., El-DeiryW.S.. Apoptotic death of tumors cells correlates with chemosensitivity independent of p53 or Bcl-2.Clin Cancer Res1996; 2: 623–33.
11.
JamiesonL., CarpenterL., BidenJ.T., FieldsP.A.. Protein kinase C is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis.J Biol Chem1999; 274: 3927–30.
SenchekovA., LitvakA.D., CabotC.M.. Targeting ceramide metabolism - a strategy for overcoming drug resistance.J Natl Cancer Inst2001; 93: 347–57.
14.
SteinmanR.A., JohnsonD.E.. p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP and inhibits leukemic apoptosis.Mol Med2000; 6: 736–49.
15.
NaganeM., LevitzkiA., GazitA., CaveneeK.W., Su HuangH.J.. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-Xl and caspase-3-like proteases.Proc Natl Acad Sci1998; 95: 5724–29.
16.
ZieglerM., OeiS.L.. A cellular survival switch: poly(ADP-ribosyl)ation stimulates repair and silences transcription.Bioessays2001; 23: 543–8.
17.
GaoG., Ping DouQ.. G1 phase-dependent expression of Bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells.Mol Pharm2000; 58: 1001–13.
18.
PickardM., DiveC., KinsellaA.R.. Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis.Br J Cancer1995; 72: 1389–96.
19.
BediA., BarderP.J., BediC.G.. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents.Blood1995; 86: 1148–58.
20.
ShahA.M., SchwartzK.G.. Cell-cycle-mediated drug resistance: An emerging concert in cancer therapy.Clin Cancer Res2001; 7: 2168–81.
21.
ColganD.F., MurphyK.G.K., PrivesC., ManleyJ.L.. Cell cycle related regulation of poly(A) polymerase by phosphorylation.Nature1998; 384: 282–5.
22.
ColganD.F., MurphyK.G.K., ZhaoW., PrivesC., ManleyJ.L.. Inhibition of poly(A) polymerase requires p34cdc2/cyclin B phosphorylation of multiple consensus and non-consensus sites.EMBO J1998; 17: 1053–62.
23.
BondL.G., PrivesC., ManleyL.J.. Poly(A) polymerase is dependent on novel interactions with cyclins.Mol Cell Biol2000; 20: 5310–20.
24.
ZhaoW., ManleyJ.L.. Deregulation of poly(A) polymerase interferes with cell growth.Mol Cell Biol1998; 18: 5010–20.
25.
MizrahiN., MooreC.. Posttranslational phosphorylation and ubiquitination of the S. cerevisiae poly(A) polymerase at the S/G2 stage of the cell cycle.Mol Cell Biol2000; 20: 2794–802.
26.
Casciola-RosenL.A., MillerK.D., AnhaltG.J., RossenA.. Specific cleavage of the 70kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death.J Biol Chem1994; 269: 30757–66.
27.
MoulandJ.A., CoadyM., YaoX-J, CohenA.E.. Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression.Virology2002; 292: 321–30.
28.
AtabasidesH., TsiapalisC.M., HavredakiM.. Dephosphorylation, proteolysis, and reduced activity of poly(A) polymerase associated with U937 cell apoptosis.Exp Cell Res1998; 244: 433–40.
29.
AtabasidesH., TsiapalisC.M., HavredakiM.. Poly(A) polymerase specifically implicated in the mechanism of chemotherapeutic drug action during cell apoptosis.Int J Biol Markers2000; 15: 10–4.
30.
BalatsosN.A.A., HavredakiM., TsiapalisC.M.. Anticancer drug action on poly(A) polymerase activity and isoforms during HeLa and WISH cell apoptosis.Int J Biol Markers2000; 15: 171–8.
31.
BalatsosN.A.A., HavredakiM., TsiapalisC.M.. Early 5-fluorouracil-induced changes of poly(A) polymerase in HeLa and WISH cells.Int J Biol Markers2000; 15: 294–9.
32.
BalatsosN.A.A., LallasG., HavredakiM., TsiapalisC.M.. Drug action on poly(A) polymerase activity and isoforms during U937 cell apoptosis.J Exp Clin Cancer Res2001; 20: 63–9.
33.
KleimanF.E., ManleyJ.L.. Functional interaction of BRCA1-associated BARD 1 with polyadenylation CstF-50.Science1999; 285: 1576–9.
34.
KleimanF.E., ManleyJ.L.. The BARD 1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression.Cell2001; 104: 743–53.
35.
SaitochS., ChabesA., McDonaldW.H., ThelanderL., YatesR.J., RussellP.. Cid13 is a cytoplasmic poly(A) polymerase that regulates ribonucleotide reductase mRNA.Cell2002; 109: 563–73.
36.
TakagakiY., ManleyL.J.. Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation.Mol Cell1998; 6: 761–71.
37.
BarabinoS.M.L., KellerW.. Last but not least: regulated poly(A) tail formation.Cell1999; 99: 9–11.
38.
WahleE., RuegseggerU.. 3′-end processing of pre-mRNA in eukaryotes.FEMS Microbiol Rev1999; 23: 277–95.
39.
ZhaoJ., HymanL., MooreC.. Formation of mRNA 3′ ends in eukaryotes: Mechanism, regulation and interrelationships with other steps in mRNA synthesis.Microbiol Mol Biol Rev1999; 63: 405–45.
40.
ProudfootN.. Connecting transcription to mRNA processing.Trends Biochem Sci2000; 25: 290–3.
41.
ConneB., StutzA., VassalliJ.D.. The 3′ untranslated region of messenger RNA: A molecular “hot spot” for pathology.Nature Med2000; 6: 637–41.
42.
BallantyneS., BilgerA., AstromJ., VirtanenA., WickensM.. Poly(A) polymerase in the nucleus and cytoplasm of frog oocytes: dynamic changes during oocyte maturation and early development.RNA1995; 1: 64–78.
43.
KashiwabaraS., ZhuangT., YamagataK., NoguchiJ., FukamizuA., BabaT.. Identification of a novel isoform of poly(A) polymerase, TPAP, specifically present in the cytoplasm of spermatogenetic cells.Dev Biol2000; 328: 106–15.
44.
LeeX.J., LeeY., ChungJ.H.. An intronless gene encoding a poly(A) polymerase is specifically expressed in testis.FEBS Lett2000; 487: 287–92.
45.
KyriakopoulouC.B., NordvargH., VirtanenA.. A novel nuclear human poly(A) polymerase.J Biol Chem2001; 276: 33504–11.
46.
TopalianL.S., KanekoS., GonzalesI.M., BondL.G., WardY., ManleyL.J.. Indentification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors.Mol Cell Biol2001; 21: 5614–23.
47.
PhilipsA.V., CooperT.A.. RNA processing and human disease.Cell Mol Life Sci2000; 57: 235–49.
48.
ColganD., ManleyJ.. Mechanisms and regulation of mRNA polyadenylation.Genes Dev1997; 11: 2755–66.
49.
TsiapalisC.M.. Regulation of mRNA polyadenylation-deadenylation.Mol Biol Rep1987; 12: 291–8.
50.
JacobS.T., TernsM.P., MaguireK.A.. Polyadenylate polymerases from normal and cancer cells and their potential role in messenger RNA processing: a review.Cancer Res1989; 49: 2827–33.
51.
TrangasT., CourtisN., PangalisG.A.. Polyadenylic acid polymerase activity in normal and leukemic human leukocytes.Cancer Res1984; 44: 3691–7.
52.
ScorilasA., TalieriM., ArdavanisA.. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer.Cancer Res2000; 60: 5427–33.
PendurthiU., AlokD., RaoU.M.. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase.Proc Natl Acad Sci1997; 94: 12598–603.
55.
LevensonR., KernenJ., HousmanD.. Synchronization of MEL cell commitment with cordycepin.Cell1979; 18: 1073–8.
56.
KuznetsovD.A., MusajevN.. The molecular brain mRNA processing damage followed by the suppression of post-transcriptional poly(A) synthesis with cordycepin.Int J Neurosci1990; 51: 53–67.
57.
NiitsuN., UmedaM., HonmaY.. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.Leukemia Res2000; 24: 1–9.
58.
NiitsuN., Yamamoto-YamaguchiY., KasukabeT., Okabe-KadoJ., UmedaM., HonmaY.. Antileukemic efficacy of 2′-deoxyconformycin in monocytic leukemia cells.Blood2000; 96: 1512–6.
59.
KodamaE.N., McCaffreyR.P., YusaK., MitsuyaH.. Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells.Biochem Pharmacol2000; 59: 273–81.
60.
KocY., UrbanoA.G., SweeneyE.B., McCaffreyR.. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells.Leukemia1996; 10: 1019–24.
61.
LallasG.C.. Strategies for chemotherapeutic drug action and development of drug resistance in various cell lines: mRNA polyadenylation and cell apoptosis. Doctoral thesis, University of Athens Medical School, Department of Biological Chemistry, 2003.
62.
GerlierD., ThomassetN.. Use of MTT colorimetric assay to measure cell activation.J Immunol Meth1983; 94: 57–63.
63.
BaryM.A., BehnkeC.A., EastmanA.. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.Biochem Pharmacol1990; 40: 2353–62.
64.
LazebnicY.A., ColeS., CookeC.A., NelsonW.G., EarnshawW.C.. Nuclear events of apoptosis in cell-free mitotic extracts: A model system for analysis of the active phase of apoptosis.J Cell Biol1993; 123: 7–22.
ChouR.H., HuangH.. Restoration of p53 tumor suppressor pathway in human cervical carcinoma cells by sodium arsenite.Biochem Biophys Res Com2002; 293: 298–306.
67.
PollaB.S., KantengwaS., FrancoisD.. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury.Proc Natl Acad Sci1996; 93: 6458–63.
68.
SchulW., van DrielR., de JongL.. A subset of poly(A) polymerase is concentrated at sites of RNA synthesis and is associated with domains enriched in splicing factors and poly(A) RNA.Exp Cell Res1998; 238: 1–12.
69.
JugeF., ZaessingerS., TemmeC., WahleE., SimoneligM.. Control of poly(A) polymerase level is essential to cytoplasmic polyadenylation and early development in Drosophila.EMBO J2002; 21: 6603–13.
70.
DickinsonK.S., ThompsonS.R., GrayN.K., WickensM.. Poly(A) polymerase and the regulation of cytoplasmic polyadenylation.J Biol Chem2001; 276: 41810–6.
71.
SonoyamaJ., MatsumuraI., EzoeS.. Functional cooperation among Ras, STAT5 and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.J Biol Chem2002; 277: 8076–82.
72.
TaylorM.H., BuckwalterM.R., StephensonA.C., HartJ.K., TaylorB.J., O'NeilK.L.. Radiation-induced apoptosis in MOLT–4 cells requires de novo protein synthesis independent of de novo RNA synthesis.FEBS Lett2002; 514: 199–203.
73.
SchiavoneN., RosiniP., QuattroneA.. A conserved AUrich element in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis.FASEB J2000; 14: 174–84.
